comparemela.com

Pierre Boulud News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BioMérieux: growth of over 6% in Q1 -April 09, 2024 at 01:55 am EDT

bioMérieux reports sales of 965 million euros for the first quarter of 2024, up 6.6% on a reported basis and 9.8% at constant exchange rates and scope of consolidation, with organic growth ahead of.

Pierre boulud

IP : Oxford Nanopore - BioMérieux makes strategic investment in Oxford Nanopore -October 19, 2023 at 05:43 am EDT

19 Oct 2023 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION Oxford, UK and Marcy-l Étoile, France, 19 October 2023. Oxford Nanopore Technologies.

United kingdomCity ofAymeric fichetGordon sangheraOlivier rescaniOxford nanoporeOxford nanopore technologieTom murrayPierre bouludOlivia petersFinancial conduct authorityLondon stock exchangeLondon stock exchange admissionNanopore technologiesOfficial listCity code

Oxford Nanopore secures £70m investment from French biotech group

As a result of the investment, bioMérieux now owns 3.5 per cent of Oxford Nanopore s shares and expects to increase this from time to time, subject to availability and price.

City ofUnited kingdomPierre bouludOxford nanoporeGordon sangheraUniversity of oxfordOxford universityOxford nanopore technologiesMayo clinicInteractive investor

Oxford Nanopore secures £70m investment from French biotech group

Oxford Nanopore secures £70m investment from French biotech group
thisismoney.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thisismoney.co.uk Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomGordon sangheraPierre bouludOxford nanoporeOxford universityUniversity of oxfordOxford nanopore technologiesMayo clinicInteractive investor

BioMerieux : First-Half 2023 Results -Today at 02:42 am

bioMérieux - First-Half 2023 Results €1,770 million in first-half 2023 sales, up 8.3% like-for-like; organic growth excluding.

Salt lake cityUnited statesAsia pacificPierre bouludInnorth americaJennifer zinnLab efficiencyFor panelClinical laboratory improvement amendmentsDrug administrationR panel miniChief executive officerLatin americaBiofire defenseIncluding europeMiddle east

vimarsana © 2020. All Rights Reserved.